Thrombin receptors and their antagonists: an update on the patent literature

Bibliography

• Holinstat M, Voss B, Bilodeau ML, Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway. Mol Pharmacol 2007;71:686-94
   PubMedGoogle Scholar
• McNamara CA, Sarmbock IJ, Gimple LW, Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;9:94-8
   Google Scholar
• Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800-14
   PubMed Web of Science ®Google Scholar
• Cenac N, Cellars L, Steinhoff M, Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis 2005;11:792-8
   Google Scholar
• Ramachandran R and Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008;53(S1):S263-82
   Google Scholar
• Kaufmann R, Rahn S, Pollrich K, Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007;211(3):699-707
   Google Scholar
• Choi MS, Kim YE, Lee WJ, Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes. Brain Res Bull 2008;76(4):368-75
   Google Scholar
• Vergnolle N, Wallace JL, Bunnett NW, Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001;22:146-52
   PubMed Web of Science ®Google Scholar
• Asokananthan N, Graham PT, Stewart DJ, Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002;168:3577-85
   PubMed Web of Science ®Google Scholar
• Derian CK, Damiano BP, Addo MF, Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003;304:855-61
   PubMed Web of Science ®Google Scholar
• Darmoul D, Gratio V, Devaud H, Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003;162:1503-13
   PubMedGoogle Scholar
• Vergnolle N, Cellars L, Mencarelli A, A role for proteinase-activated receptor–1 in inflammatory bowel diseases. J Clin Invest 2004;114:1444-56
   PubMed Web of Science ®Google Scholar
• Hamilton JR. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev 2009;23:61-5
   PubMed Web of Science ®Google Scholar
• Riewald M, Petrovan RJ, Donner A, Ruf W. Activated protein C signals through the thrombin receptor PAR-1 in endothelial cells. J Endotoxin Res 2003;9(5):317-21
   Google Scholar
• Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105(8):3178-84
   Google Scholar
• Maryanoff BE. Adventures in drug discovery: potent agents based on ligands for cell-surface receptors. Acc Chem Res 2006;39:831-40
   Google Scholar
• Hoekstra WJ, Hulshizer BL. Preparation of azole peptidomimetics as thrombin receptor antagonists. US6017890; 2000
   Google Scholar
• Hoekstra WJ, Maryanoff BE, McComsey DF, Zhang H. Preparation of novel indole peptidomimetics as thrombin receptor antagonists. WO2001000657; 2001
   Google Scholar
• Zhang H, Maryanoff BE, Pandey A, Scarborough RM. Preparation of indazole peptidomimetics as thrombin receptor antagonists. WO2001000656; 2001
   Google Scholar
• Zhang H, Maryanoff BE, Mccomsey DF, White KB. Preparation of benzimidazolone peptidomimetics as thrombin receptor antagonists. WO2001000659; 2001
   Google Scholar
• Andrade-Gordon P, Maryanoff BE, Derian CK, Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 1999;96:12257-62
   PubMed Web of Science ®Google Scholar
• Zhang HC, McComsey DF, White KB, Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide. Bioorg Med Chem Lett 2001;11(16):2105-09
   Google Scholar
• Zhang HC, Derian CK, Andrade-Gordon P, Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J Med Chem 2001;44:1021-4
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, Zhang H, Andrade-Gordon P, Derian CK. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem 2003;1:13-36
   Google Scholar
• Kuliopulos A, Covic L. G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same. US6864229; 2005
   Google Scholar
• Covic L, Gresser AL, Talavera J, Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane tethered peptides. PNAS 2002;99:643-8
   PubMed Web of Science ®Google Scholar
• Covic L, Misra M, Badar J, Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002;8(10);1161-5
   Google Scholar
• Boire A, Covic L, Agarwal A, PAR-1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13
   PubMed Web of Science ®Google Scholar
• Agarwal A, Covic L, Sevigny LM, Targeting a metalloprotease-PAR-1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 2008;7(9):2746-57
   Google Scholar
• Ahn H, Arik L, Boykow G, Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg Med Chem Lett 1999;9:2073-8
   Google Scholar
• Strande JL, Hsu A, Su J, SCH 79797, a selective PAR-1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol 2007;102:350-8
   PubMed Web of Science ®Google Scholar
• Zania P, Kritikou S, Flordellis CS, Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006;318:246-54
   PubMedGoogle Scholar
• Di Serio C, Pellerito S, Duarte M, Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol 2007;101:63-9
   PubMedGoogle Scholar
• Maryanoff BE, Zhang H, McComsey DF. Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists. WO2002068425; 2002
   Google Scholar
• Barrow JC, Connolly T, Freidinger RM, Preparation of aryl-isoxazolyl-amines and use as thrombin receptor antagonists. GB2356198; 2001
   Google Scholar
• Nantermet PG, Barrow JC, Selnick HG. Preparation of pyrrolidinecarboxamides, piperidinecarboxamides, and related compounds as thrombin receptor antagonists. US2001044454; 2001
   Google Scholar
• Barrow JC, Nantermet PG, Selnick HG, Preparation of N-aryl-N′-arylethylurea derivatives as thrombin receptor antagonists. US2002007045; 2002
   Google Scholar
• Suzuki S, Kotake M, Miyamoto M, Preparation of cyclic amidine derivatives as thrombin receptor antagonists. WO2002085850; 2002
   Google Scholar
• Suzuki S, Kotake M, Miyamoto M, Preparation of 2-iminopyrrolidine derivatives as thrombin receptor antagonists. WO2002085855; 2002
   Google Scholar
• Suzuki S, Kotake M, Miyamoto M, Preparation of 2-iminoimidazole derivatives as thrombin receptor antagonists. WO2002088092; 2002
   Google Scholar
• Husted S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 2007;9:D20-27
   Web of Science ®Google Scholar
• Serebruany VL, Kogushi M, Dastros-Pitei D, The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009;102(1):111-9
   Google Scholar
• Chackalamannil S, Asberom T, Xia Y, Preparation of himbacine analogs as thrombin receptor antagonists. US6063847; 2000
   Google Scholar
• Chackalamannil S, Chelliah MV, Clasby MC, Xia Y. Preparation of himbacine analogues as thrombin receptor antagonists. WO2003033501; 2003
   Google Scholar
• Chelliah MV, Chackalamannil S, Xia Y, Preparation of constrained himbacine analogs as thrombin receptor antagonists. US2005267155; 2005
   Google Scholar
• Chackalamannil S, Wang Y, Greenlee WJ, Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51:3061-4
   PubMed Web of Science ®Google Scholar
• Becker RC, Moliterno DJ, Jennings LK, Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;14(373):919-28
   Google Scholar
• The TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009;158(3):327-34
   Google Scholar
• Morrow D, Scirica B, Fox K, Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009;158(3):335-41
   PubMed Web of Science ®Google Scholar
• Hezi-Yamit A, Wong J. Local delivery of PAR-1 antagonists to treat vascular complications. US2009297576; 2009
   Google Scholar
• Chackalamannil S, Wang Y. Oxazoloisoquinoline derivatives as thrombin receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. US2007149518; 2007
   Google Scholar
• Chackalamannil S, Chelliah MV, Xia Y. Spiroheterocyclic-decalin compounds as thrombin receptor antagonists and their preparation and pharmaceutical compostions. WO2006105217; 2006
   Google Scholar
• Chelliah MV, Chackalamannil S, Xia Y. Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists. US2007232635; 2007
   Google Scholar
• Xia Y, Chelliah MV, Chackalamannil S. Fused ring thrombin receptor antagonists. US2007244163; 2007
   Google Scholar
• Chackalamannil S, Chelliah MV, Wang Y, Xia Y. Preparation of bicyclic and tricyclic himbacine derivatives as thrombin receptor antagonists. WO2008042422; 2008
   Google Scholar
• Perez M, Lamothe M, Le Grand B, Letienne R. Preparation of phenylpentadienoyl derivatives, especially phenylpentadienoylpiperazines, as proteinase-activated receptor 1 antagonists. FR2902427; 2007
   Google Scholar
• Perez M, Lamothe M, Le Grand B, Letienne R. Preparation of cinnamoylpiperazines as proteinase-activated receptor 1 antagonists. FR2902426; 2007
   Google Scholar
• Perez M, Lamothe M, Maraval C, Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem 2009;52(19):5826-36
   Google Scholar
• Perez M, Le Grand B, Letienne R. Protease activated receptor-1 antagonists for the treatment of atrial fibrillation. WO2008155335; 2008
   Google Scholar
• Heinelt U, Wehner V, Herrmann M, Preparation of triazolopyridazines as proteinase activated receptor (PAR-1) antagonists. WO2009097970; 2009
   Google Scholar
• Beri R. The use and identification of antagonists of protease-activated receptor 3 (PAR-3) for the treatment of asthma. WO2006054931; 2006
   Google Scholar
• Wu CC, Huang SW, Hwang TL, YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol 2000;130:1289-96
   Google Scholar
• Wu CC, Hwang TL, Liao CH, Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 2002;87:1026-33
   Google Scholar
• Wu CC, Hwang TL, Liao CH, The role of PAR-4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost 2003;90:299-308
   PubMedGoogle Scholar
• Peng CY, Pan SL, Guh JH, The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost 2004;92:1232-9
   PubMedGoogle Scholar
• Huang LJ, Shih ML, Chen HS, Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-angiogenic agents. Bioorg Med Chem 2006;14(2):528-36
   Google Scholar
• Chen HS, Kuo SC, Teng CM, Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem 2008;16(3):1262-78
   Google Scholar
• Wielders SJH, Bennaghmouch A, Reutelingsperger CPM, Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemost 2007;5:571-6
   PubMed Web of Science ®Google Scholar
• Strande JL, Hsu A, Su J, Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signalling. J Pharmacol Exp Ther 2008;324(3):1045-54
   Google Scholar
• Slofstra SH, Bijlsma MF, Groot AP, Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007;110(9):3176-82
   Google Scholar
• Lerner E, Reddy VB. Method for preventing and treating itch by administering a G protein-coupled protease activated receptor 4 antagonist. WO2008086069; 2008
   Google Scholar
• Xia Y, Chackalamannil S. Combination therapies comprising PAR-1 antagonists with PAR-4 antagonists for treatment of diseases assocd. with thrombosis. WO200912410; 2009
   Google Scholar
• Chackalamannil S, Xia Y, Greenlee WJ, Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 2005;48:5884-87
   PubMed Web of Science ®Google Scholar
• Howell DC, Goldsack NR, Marshall RP, Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001;159:1383-95
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Distrutti E, PAR-1 Antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004;39:365-75
   PubMed Web of Science ®Google Scholar
• Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 2009;10:988-96
   PubMed Web of Science ®Google Scholar